An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO (OrthoSpineNews)
Histogenics, a biotech developing a therapy for repairing knee cartilage using its tissue repair platform, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Histogenics would command a fully diluted market value of $158 million.The deal is 58% covered, as insiders plan to purchase $20 million worth of shares on the offering while August 2013 biotech Intrexo...
